NASDAQ:VYNT
Delisted
Vyant Bio, Inc. Stock News
$0.194
+0 (+0%)
At Close: Mar 28, 2024
Vyant Bio showcases 'promise and potential' of its drug discovery platform at Boston medical conference
09:34am, Friday, 11'th Nov 2022
Vyant Bio (NASDAQ:VYNT) Inc senior scientist Matthew Green delivered poster presentations this week at the Loulou Foundation's CDKL5 forum held in Boston. CDKL5 (cyclin-dependent kinase-like 5) defi
Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million
11:06am, Thursday, 03'rd Nov 2022
Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, allowing Reaction to expand its suite of drug disco
Vyant Bio Announces One-for-Five Reverse Stock Split
08:30am, Tuesday, 01'st Nov 2022
CHERRY HILL, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex ne
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
05:30pm, Thursday, 27'th Oct 2022
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) — Vyant Bio,
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
04:30pm, Monday, 24'th Oct 2022
–To Discuss its Novel Drug Discovery Platform that is Accelerating the Process of Finding Cures for Neurogenerative Diseases CHERRY HILL, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (�
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
04:15pm, Monday, 24'th Oct 2022
- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:00am, Wednesday, 31'st Aug 2022
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neu
Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year
07:07am, Tuesday, 23'rd Aug 2022
Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early next year based on pre-clinical efficacy data and
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript
11:00pm, Monday, 22'nd Aug 2022
Vyant Bio, Inc. (NASDAQ:VYNT ) Q2 2022 Results Earnings Conference Call August 22, 2022 4:30 PM ET Company Participants Jay Roberts - President and Chief Executive Officer Andrew LaFrence - Chief Fina
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
09:29am, Friday, 19'th Aug 2022
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neu
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
08:05am, Monday, 15'th Aug 2022
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neu
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
08:00am, Thursday, 11'th Aug 2022
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neu
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q1 2022 Results - Earnings Call Transcript
08:39pm, Monday, 16'th May 2022
Vyant Bio, Inc. (NASDAQ:VYNT ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Robert Fremea
Vyant Bio ends 1Q with $16.4M in cash to fund small molecule therapeutics research for neurological diseases
10:40am, Monday, 16'th May 2022
Vyant Bio (NASDAQ:VYNT) Inc ended its first quarter with $16.4 million after a busy three months that saw it progress the discovery of small molecule therapeutics to treat neurological diseases. In
Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022
04:01pm, Tuesday, 10'th May 2022
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neuro